// App-Quantinova.ai

2751 : Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer

Researchers

Presenter

  • Balraj Singh

Principal Investigators

  • Vanessa N. Sarli

  • Anthony Lucci

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Acute lymphoblastic leukemia

  • Breast cancer

  • Inflammatory bowel disease

  • Solid malignancies

Biomarkers

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • 6-mercaptopurine

  • Vidaza

  • Doxorubicin

  • Paclitaxel

  • Glutamine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved